Assays for difficult to screen enzyme targets
Eliminating false positives from enzyme-coupled assays.
Researchers deprioritize good targets all the time—not because the biology is wrong, but because there’s no methods with sufficient throughput and signal-to-noise to enable screening. The fallback is LC-MS. Mass spectrometry is used in drug discovery not because teams want to use it, but because they have no other option.
We build direct biological sensors for metabolites and enzyme products that cannot be measured reliably with conventional assays. Direct and kinetic detection of your molecule of interest: no enzyme-coupled reactions, no secondary readouts.
Targets in development
Proprietary methods, industry-leading throughput
We’ve developed proprietary methods for building FRET-based assays against drug targets. Our assays directly measure molecule concentration—no coupled enzyme cascades adding noise to your signal. Teams use Percepta to stop troubleshooting the assay and start making chemistry decisions.
How do we construct these assays? We developed state of the art methods to optimize millions of assay variations simultaneously. We leverage deep learning on these datasets to guide future iterations of assay optimization.
Reach out to learn how our proprietary assay platforms can support your research .
Start a Conversation
Trusted by Innovators in Science
Researchers and partners trust our platform for precision, speed, and reliable results.
The platform’s throughput and data quality are outstanding. We were able to generate meaningful results much faster than with traditional assay methods
“Their FRET-based assays enabled us to work with targets that were previously very difficult to measure accurately.”
“The combination of real-time measurement and data-driven analysis gave us a clear advantage in target validation and assay development.”
